Biofrontera AG
BFFTF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.04 | -0.00 | -0.04 |
| FCF Yield | -4,879.69% | -633.93% | -1,201.92% | -611.06% |
| EV / EBITDA | -0.28 | -14.24 | 0.61 | 0.81 |
| Quality | ||||
| ROIC | -149.88% | -72.23% | -65.64% | -42.27% |
| Gross Margin | 48.80% | 47.04% | 47.13% | 51.90% |
| Cash Conversion Ratio | 1.24 | 25.31 | 0.71 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.23% | 15.01% | -2.72% | 2,661,213.92% |
| Free Cash Flow Growth | -53.35% | 39.25% | -116.07% | 67.63% |
| Safety | ||||
| Net Debt / EBITDA | -0.26 | -16.98 | 0.67 | 1.08 |
| Interest Coverage | -37.80 | -114.77 | -71.81 | -2.88 |
| Efficiency | ||||
| Inventory Turnover | 1.60 | 2.12 | 2.86 | 1.28 |
| Cash Conversion Cycle | 95.10 | 235.85 | 215.51 | 288.22 |